Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium-Glucose CoTransporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production
NCT03852901Phase 1Completed
- Sponsor
- National Institute on Aging
- Start
- Mar 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of empagliflozin in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI), sponsored by National Institute on Aging. Primary endpoint: Change in Serum β-hydroxybutyrate (BHB) at 14 days. Started Mar 2019; status: completed.
02
Drugs
empagliflozin
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT03852901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03852901.